DHA-PQP dispersible

Alfasigma

Legend
Product vision
  • 3-day cure, artemisinin-based combination therapy (dihydroartemisinin-piperaquine)
Dosing

  • Once-daily for 3 days
Efficacy

  • Efficacy in adults established. Pharmacokinetic bridging strategy to establish paediatric dose
Key features

  • Anticipated comparatively long post-treatment protection
Challenges
  • Potential cardiac monitoring restrictions
  • Confirmed piperaquine resistance in Greater Mekong Sub-region (GMS)
Status
  • Pharmacokinetic studies in children completed
  • Dossier under development for submission to European Medicines Agency (EMA)
Next milestone

  • Submission to EMA 
MMV Project Director
  • Adam Aspinall (ad interim)